Skip to content

BCBS North Carolina

Does BCBS North Carolina cover Mounjaro for Type 2 Diabetes?

Yes. BCBS North Carolina covers Mounjaro for type 2 diabetes with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy documents

  • GLP-1 Agonists Nc Standard

    BCBS North Carolina · PA policy · Employer

    Verified June 2, 2026.

    View PDF Download Original insurer source

  • GLP-1 Agonists – Bydureon, Mounjaro, Rybelsus Prior Authorization Criteria (With Quantity Limit) – Medicare Part D

    BCBS North Carolina · PA policy · Medicare Part D and Medicare Advantage

    Verified June 2, 2026.

    View PDF Download Original insurer source
  • Employer: Covered (preferred drug). See the qualification pathways below.
  • Medicare Part D and Medicare Advantage: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Mounjaro for Type 2 Diabetes (3 plan types)

Applies to Employer plans.

Covered (preferred drug)

Qualification pathways

You can qualify through any one of these.

New patient - prior therapy requirement

All of:

  • Diagnosis of type 2 diabetes mellitus (medical record documentation required)
  • Requested product will not be taken concomitantly with a DPP-4 containing agent
  • Requested product will not be taken concomitantly with another GLP-1 agonist

Plus any one of:

  • Patient has tried and had an inadequate response, intolerance, or hypersensitivity to an agent containing metformin, sulfonylurea, or insulin
  • Patient has an FDA labeled contraindication to metformin
  • Patient has a diagnosis of, or is at high risk for, atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, and/or MASH

Continuity of care - currently on therapy

All of:

  • Diagnosis of type 2 diabetes mellitus (medical record documentation required)
  • Prescriber states patient is currently being treated with the requested agent within the past 90 days and is at risk if therapy is changed
  • Requested product will not be taken concomitantly with a DPP-4 containing agent
  • Requested product will not be taken concomitantly with another GLP-1 agonist

Documentation to bring

  • Medical record documentation of type 2 diabetes mellitus diagnosis
  • Documentation of prior trial with inadequate response, intolerance, or hypersensitivity to metformin, sulfonylurea, or insulin OR FDA labeled contraindication to metformin OR diagnosis of/high risk for ASCVD, heart failure, CKD, or MASH (OR attestation that patient is currently on this agent within the past 90 days and at risk if changed)
  • Attestation that requested product will not be taken concomitantly with a DPP-4 containing agent
  • Attestation that requested product will not be taken concomitantly with another GLP-1 agonist

Quantity limits

  • 2.5mg/0.5mL — 2 mL (4 pens)
  • 5mg/0.5mL — 2 mL (4 pens)
  • 7.5mg/0.5mL — 2 mL (4 pens)
  • 10mg/0.5mL — 2 mL (4 pens)
  • 12.5mg/0.5mL — 2 mL (4 pens)
  • 15mg/0.5mL — 2 mL (4 pens)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months

Not covered when

  • Concomitant use with DPP-4 containing agent
  • Concomitant use with another GLP-1 agonist

Policy note: Mounjaro is listed as a preferred product per the April 2023 policy update. Indication expanded to include pediatric patients 10 years and older per Jan 2026 update. Approved for T2DM only per this policy; weight loss is not an approved indication under this policy document.

Policy effective May 1, 2026 · verified June 2, 2026 · source: GLP-1 Agonists Nc Standard · View policy document (PDF)

Applies to Medicare Part D and Medicare Advantage plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Existing patient — claim evidence of current use

All of:

  • Medication will NOT be used for weight loss alone
  • Patient has a diagnosis of type 2 diabetes mellitus
  • Claim evidence shows patient is currently being treated with the requested medication within the past 180 days
  • PA applies to new starts only (existing-use pathway exception)

Existing patient — prescriber attestation of current use

All of:

  • Medication will NOT be used for weight loss alone
  • Patient has a diagnosis of type 2 diabetes mellitus
  • Prescriber states patient is currently being treated with the requested medication within the past 180 days
  • PA applies to new starts only (existing-use pathway exception)

New start — prior non-GLP-1 oral diabetes medication requirement

All of:

  • Medication will NOT be used for weight loss alone
  • Patient has a diagnosis of type 2 diabetes mellitus
  • Patient does NOT have any FDA labeled contraindications to the requested medication
  • Patient will NOT be using the requested medication in combination with another GLP-1 agonist
  • Patient will NOT be using the requested medication in combination with a DPP-4 inhibitor

Plus any one of:

  • Medication history includes use of a non-GLP-1 oral diabetes medication (e.g., metformin, glipizide) within the past 90 days
  • Patient had an ineffective treatment response to a non-GLP-1 oral diabetes medication
  • Patient has an intolerance or hypersensitivity to a non-GLP-1 oral diabetes medication
  • Patient has an FDA labeled contraindication to a non-GLP-1 oral diabetes medication

Documentation to bring

  • Documentation of type 2 diabetes mellitus diagnosis
  • Documentation that the medication will NOT be used for weight loss alone
  • ONE of: claim history showing current use within past 180 days, OR prescriber attestation of current use within past 180 days, OR evidence of prior/current non-GLP-1 oral diabetes medication use within past 90 days OR documentation of ineffective response, intolerance, hypersensitivity, or FDA-labeled contraindication to non-GLP-1 oral diabetes medication
  • Confirmation that patient has no FDA labeled contraindications to the requested medication (for new starts)
  • Confirmation that patient will not use the medication in combination with another GLP-1 agonist (for new starts)
  • Confirmation that patient will not use the medication in combination with a DPP-4 inhibitor (for new starts)
  • If requesting quantity above program limit: prescriber-provided information supporting higher dose for the requested indication, and documentation that lower quantity of higher strength cannot achieve the requested dose

Approval and renewal

  • Initial approval: 12 months

Not covered when

  • Use for weight loss alone is excluded
  • Combination use with another GLP-1 agonist or GLP-1-containing medication is excluded
  • Combination use with a DPP-4 inhibitor or DPP-4-containing medication is excluded
  • Use in patients with FDA labeled contraindications to the requested medication is excluded

Policy note: PA applies to new starts only. The policy lists oral diabetes medications broadly as acceptable step therapy alternatives to metformin, including: sulfonylureas, biguanides, meglitinide analogues, alpha-glucosidase inhibitors, DPP-4 inhibitors, bromocriptine, TZDs, SGLT2 inhibitors, and various combination products. Patients currently on the requested medication (within 180 days) qualify via claim history or prescriber attestation without needing to meet the prior oral diabetes medication requirement. Quantity limits apply per program; higher doses may be approved if a lower quantity of a higher strength cannot achieve the requested dose and prescriber provides clinical justification.

verified June 2, 2026 · source: GLP-1 Agonists – Bydureon, Mounjaro, Rybelsus Prior Authorization Criteria (With Quantity Limit) – Medicare Part D · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS North Carolina cover Mounjaro?
Yes. BCBS North Carolina covers Mounjaro for type 2 diabetes with prior authorization. Other policy requirements and your plan's benefits also apply.
How long does a Mounjaro approval last with BCBS North Carolina?
Type 2 Diabetes — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months. Type 2 Diabetes — Applies to Medicare Part D and Medicare Advantage plans. Initial approval: 12 months.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS North Carolina: Ozempic, Wegovy, Zepbound

Mounjaro under other plans: BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Kansas, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota

All insurance plans · All medications

Summary of BCBS North Carolina's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.